Last --
Change Today 0.00 / 0.00%
Volume 0.0
7777 On Other Exchanges
7777 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

3-d matrix ltd (7777) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3-D MATRIX LTD (7777)

Related News

No related news articles were found.

3-d matrix ltd (7777) Related Businessweek News

No Related Businessweek News Found

3-d matrix ltd (7777) Details

3-D Matrix, Ltd. develops self-assembling peptides technology. It offers PuraMatrix, a self-assembling peptide hydrogel. The company is also developing various technologies for use in the fields of surgical and medical, regenerative medicine, cell therapy, and drug delivery systems. 3-D Matrix, Ltd. was founded in 2004 and is based in Tokyo, Japan.

35 Employees
Last Reported Date: 07/25/14
Founded in 2004

3-d matrix ltd (7777) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

3-d matrix ltd (7777) Key Developments

3-D Matrix, Ltd. Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015

3-D Matrix, Ltd. Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015 . Venue: Omni Berkshire Place, 21 East 52nd Street at Madison Ave, New York, NY 10022, United States. Speakers: Keiji Nagano, Founder and Chairman.

3-D Matrix, Ltd. Announces Suspension of Patient Enrolment in the Clinical Trial of Mucous Membrane Protuberance Material (TDM-641)

3-D Matrix, Ltd. announced that then company have decided to suspend the enrolment of new patients in the on-going clinical trial of the endoscopic mucosal resection aid "Mucous Membrane Protuberance Material (development code: TDM-641)" which has been announced to start in Japan as of December 11, 2014 and that the company will notify Pharmaceuticals and Medical Devices Agency, Japan as of February 17, 2015. This clinical trial began in December 2014 to evaluate and validate the safety and efficacy of TDM-641 as endoscopic mucosal resection aid used in endoscopic treatment (Endoscopic Mucosal Resection; EMR and Endoscopic Submucosal Dissection; ESD). Since adequate results for the efficacy, as expected from the preclinical data, have not been provided, the company have decided to suspend the trial voluntarily in order to review and adjust the product specification.

3-D Matrix, Ltd. Reports Consolidated Earnings Results for the Six Months Ended October 31, 2014; Provides Earnings Guidance for the Full Year Ending April 30, 2015

3-D Matrix, Ltd. reported consolidated earnings results for the six months ended October 31, 2014. For the quarter, the company reported business revenues of JPY 0 million compared to JPY 49 million a year ago. Operating loss was JPY 1,004 million compared to JPY 676 million a year ago. Ordinary loss was JPY 984 million compared to JPY 701 million a year ago. Net loss was JPY 1,148 million compared to JPY 701 million a year ago. Basic net loss per share was JPY 55.46 compared to JPY 36.19 a year ago. Loss before income taxes and minority interests was JPY 1,144.9 million compared with JPY 701.3 million a year ago. Net cash used in operating activities was JPY 976.1 million compared with JPY 930.5 million a year ago. Purchase of property, plant and equipment was JPY 4.8 million compared with JPY 7.5 million a year ago. Purchase of intangible assets was JPY 18.3 million compared with JPY 15.7 million a year ago. The company provided earnings guidance for the full year ending April 30, 2015. For the year, the company expects business revenues of JPY 10,418 million, operating income of JPY 4,483 million, ordinary income of JPY 4,466 million, net income of JPY 3,564 million and net income per share of JPY 168.04.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
7777:JP ¥1,807.00 JPY -39.00

7777 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 7777.
View Industry Companies

Industry Analysis


Industry Average

Valuation 7777 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 633.8x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 538.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 3-D MATRIX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at